Xcout Intel
OM1, Inc.
OM1, Inc. is an insights-driven technology and data company headquartered in Boston, Massachusetts, that specializes in outcome management and uses artificial intelligence and real-world data in healthcare.
Subscribe to see OM1, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
OM1, Inc. at a glance
OM1, Inc. is a healthcare company headquartered in United States. It has raised at least $171M across the 4 funding rounds on record. Its most recent funding round raised $85M in July 2021. Xcout tracks 13 named people at OM1, Inc., including Catherine Richards, PhD, MPH (President and COO).
OM1, Inc. leadership
- Catherine Richards, PhD, MPHPresident and COO
- Dennis ReillyChief Financial Officer
- Eric SchrockChief Technology Officer
- Hunter LaneChief Product Officer
- Carl Marci, MDChief Clinical Officer, Chief Psychiatrist and Managing Director of Mental Health and Neuroscience
- Costas Boussios, PhDChief Data Scientist
7 more named people on record for OM1, Inc., with roles, board committees and tenure — see the full roster →
OM1, Inc. funding rounds
At least $171M raised across the 4 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $85M | — | |
| Series C | $50M | 4 named | |
| Series B | $21M | — | |
| Series A | $15M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
OM1, Inc. competitors
A few of OM1, Inc.'s closest competitors — see the full list of competitors and alternatives →
Concerto HealthAI was a healthcare technology company that used artificial intelligence and real-world data to support drug development and precision medicine. It primarily served biopharmaceutical companies, helping them generate clinical evidence and identify or stratify patients, particularly in oncology.
QMENTA is an all-in-one governed imaging platform built by neuroscientists to manage clinical trial data and run artificial intelligence workflows. Headquartered in Boston, Massachusetts, the company helps remove delays from imaging stages in medical research.
Triomics, Inc. is a U.S. healthcare technology company that uses artificial intelligence and natural-language processing to structure oncology data from clinical records and genomic reports. Its platform serves cancer centers, oncologists, and life-sciences organizations by supporting precision-oncology workflows such as clinical-trial matching and patient identification.
OmniScience is a software development company headquartered in Houston, Texas, within the Texas Medical Center innovation hub. The firm provides specialized life sciences technology solutions designed to advance clinical research, data management, and healthcare analytics.
GNS Healthcare, Inc. is a U.S. healthcare analytics and artificial-intelligence company that uses causal machine learning and real-world data to support clinical and business decisions. It serves life-sciences companies, healthcare providers, and payers with applications including population health management, treatment optimization, and drug-development insights.
KAID Health Inc. is a health technology company utilizing artificial intelligence to streamline chart reviews and medical data analysis. The company's main headquarters is located on Milk Street in Boston, Massachusetts.
Get OM1, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about OM1, Inc.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on OM1, Inc. in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access